Obesity pill orders are still an incredible opportunity for pharma, says Goldman's Asad Haider

back. Eli Lily be beating estimates and raising guidance for its latest quarter, but the stock tumbling to its lowest level since January 2024 after trial data for its obesity pill came in below Wall Street's expectations. Eli Liy CEO David Ricks was on Squapbox earlier today to discuss the results.Take a listen. The goal was to create an oral pill that was convenient and could be made at huge scale um really for for the mass market and had weight loss that was competitive with other single acting GLP1s and ...